Nanobiotix: Voting Rights and Shares Capital of the Company

Rhea-AI Summary

Nanobiotix, traded on NASDAQ as NBTX, reported its share structure as of June 30, 2022. The total number of outstanding shares is 34,875,872, with 36,329,077 theoretical voting rights and 36,303,371 exercisable voting rights. This data is critical for investors tracking corporate governance and voting processes. Nanobiotix is dedicated to innovative cancer therapies, particularly focusing on head and neck cancers using its proprietary nanoparticle platform.

Positive

• Company has a significant number of shares outstanding, indicating a robust investor interest.
• Total theoretical and exercisable voting rights support investor participation in corporate governance.

Negative

• None.

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS--(BUSINESS WIRE)-- Regulatory News:

Nanobiotix (Paris:NANO)(NASDAQ:NBTX)

Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights
		Total voting rights, theoretical (1)	Total voting rights, exercisable (2)
June 30, 2022	34,875,872	36,329,077	36,303,371

⁽¹⁾ The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

⁽²⁾ The total number of exercisable at a Shareholders’ Meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220708005299/en/

Nanobiotix

Nanobiotix Communications

Brandon Owens

VP, Communications

+1 (617) 852-4835

contact@nanobiotix.com

Nanobiotix Investor Relations

Kate McNeil

SVP, Investor Relations

+1 (609) 678-7388

investors@nanobiotix.com

Media Relations

France – Ulysse Communication

Pierre-Louis Germain

+ 33 (0) 6 64 79 97 51

plgermain@ulysse-communication.com

Source: Nanobiotix

FAQ

What is the current number of outstanding shares for Nanobiotix (NBTX)?

As of June 30, 2022, Nanobiotix has 34,875,872 outstanding shares.

How many theoretical voting rights does NBTX have?

Nanobiotix has 36,329,077 theoretical voting rights.

What are the exercisable voting rights for Nanobiotix as of June 30, 2022?

The exercisable voting rights for Nanobiotix are 36,303,371.

What focus area does Nanobiotix target in its therapies?

Nanobiotix focuses on cancer treatment, specifically targeting head and neck cancers.